Wyniki wyszukiwania - BazTech

Ograniczanie wyników

Znaleziono wyników: 2

Liczba wyników na stronie

Wyniki wyszukiwania

Wyszukiwano:
w słowach kluczowych: apixaban

Sortuj według:

Ogranicz wyniki do:

Development and validation of LC-MS/MS method for determination of plasma apixaban

Dzudovic Jelena, Crevar Sakac Milkica, Antunovic Marko, Repic Aleksandra, Obradovic Slobodan, Djordjevic Snezana, Savic Jelena, Dzudovic Boris

Acta Chromatographica

2022

Vol. 34, no. 3

332--337

Oral anticoagulants are a group of drugs used for the prevention and treatment of venous thrombosis and venous thromboembolism. For the last ten years, direct oral anticoagulants (DOAC) have been available and are equally effective, but significantly safer than vitamin K antagonists. In the case of an overdose, their most important side effect is still bleeding. Due to their widespread use, as well as increased toxicological importance there is a need to develop an analytical method for the determination of DOAC in biological material. The aim of this paper was to establish a method for the quantification of apixaban as one of the representatives of DOAC. The methodology of the study included the measurement of apixaban in the plasma of patients treated in the intensive care unit. Plasma apixaban concentrations were determined by LC-MS/MS technique using carbamazepine as an internal standard. Obtained validation parameters indicate that the introduced method is sensitive, reliable, precise and accurate. Using this method, apixaban can be quickly and easily detected and quantified in plasma in patients who are suspected of overdosing with this drug.

Nowe doustne leki przeciwzakrzepowe - wyzwanie dla laboratorium

Kozłowski P., Czyżewska E., Bobilewicz D.

Laboratorium - Przegląd Ogólnopolski

2014

nr 9-10

37--41

Problemy związane ze stosowaniem warfaryny były impulsem do poszukiwania leków bardziej bezpiecznych, które nie wymagałyby monitorowania w laboratorium. Dopuszczone do stosowania w Polsce trzy nowe doustne leki przeciwzakrzepowe należą do dwóch grup: bezpośrednich inhibitorów trombiny i czynnika Xa. Wprowadzenie tych leków na szeroką skalę stawia przed laboratoriami nowe wyzwania.

Problems associated with the usage of warfarin have led to the discovery of safer medicines, precluding the need for continuous laboratory monitoring. Three new drugs, belonging to two different groups: direct thrombin or factor Xa inhibitors, have been approved for use in Poland. The widespread use of these drugs has created new challenges for laboratory researchers.